CoChat

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

Open access
Fessas, Petros, Kaseb, Ahmed, Wang, Yinghong, Saeed, Anwaar, Szafron, David, Jun, Tomi, Dharmapuri, Sirish, Rafeh Naqash, Abdul, Muzaffar, Mahvish, Navaid, Musharraf, Khan, Uqba, Lee, ChiehJu, Bulumulle, Anushi, Yu, Bo, Paul, Sonal, Nimkar, Neil, Bettinger, Dominik, Benevento, Francesca, Hildebrand, Hannah, Pressiani, Tiziana, Abugabal, Yehia I, Personeni, Nicola, Huang, Yi-Hsiang, Rimassa, Lorenza, Ang, Celina, Marron, Thomas, Pinato, David J · 2020 · Journal for ImmunoTherapy of Cancer
Cited by 60

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Abstract

Background: Nivolumab is Food and Drug Administration approved in sorafenib-experienced, advanced hepatocellular carcinoma (HCC). Post-registration data of treatment in a real-world setting is lacking. Patients and methods: We performed an international, multicenter observational study to confirm safety and efficacy of nivolumab in 233 patients treated outside clinical trials from eight centers in North America, Europe and Asia. Results: Patients received nivolumab for Barcelona Clinic Liver Cancer stage C (n=191, 92.0%) and Child-Pugh (CP) A (n=158, 67.8%) or B (n=75, 32.2%) HCC as first (n=85, 36.5%) or second to fourth systemic therapy line (n=148, 63.5%). Objective response rate (ORR) was 22.4% and disease control rate was 52.1%. Median overall survival (OS) was 12.2 months (95% CI 8.4 to 16.0) and median progression-free survival was 10.1 months (95% CI 6.1 to 14.2). Treatment-related adverse events of grade >2 occurred in 26 patients (11.2%). Efficacy and safety were similar across CP classes and therapy line. OS was shorter in CP-B than A (7.3 months vs 16.3 months, p<0.001) and in post-first line use (10.4 months vs 16.3 months, p=0.05). Achievement of an objective response predicted for improved OS (25.4 months vs 13.2 months, p<0.001). Conclusions: This study confirms safety and efficacy of nivolumab in advanced HCC across various lines of therapy and degrees of liver dysfunction. Despite equal ORR and toxicity to nivolumab, patients with CP-B functional class have shorter survival than the patients with CP-A.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/jitc-2020-001033

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Fessas, P., Kaseb, A., Wang, Y., Saeed, A., Szafron, D., Jun, T., Dharmapuri, S., Rafeh Naqash, A., Muzaffar, M., Navaid, M., Khan, U., Lee, C., Bulumulle, A., Yu, B., Paul, S., Nimkar, N., Bettinger, D., Benevento, F., Hildebrand, H., Pressiani, T., Abugabal, Y. I., Personeni, N., Huang, Y.-H., Rimassa, L., Ang, C., Marron, T., & Pinato, D. J.
Venue
Journal for ImmunoTherapy of Cancer
Publisher
BMJ
Published
2020-08
Volume
8
Issue
2
Pages
e001033
ISSN
2051-1426 (ISSN-L)
OpenAlex
W3082827286
Cited by
60
References
9
FWCI
5.54
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.